What&#x27;s to Blame for Variable Home BP in Patients With Diabetes?

For the answer, click here.

Question 2:

The START trial, which recently completed enrollment, will address one of the key clinical questions in HIV management: when is the optimal time to start antiretroviral therapy.

NEXT QUESTION »

For the answer, click here.

Question 3:

At age 65 to 70 years, most men begin to report difficulties in coping with health problems, cognitive decline, and loss of a spouse.

NEXT QUESTION »

For the answer, click here.

Question 4:

Thyrotoxic periodic paralysis (TPP) is characterized by episodes of muscle weakness in persons with hyperthyroidism.

NEXT QUESTION »

For the answer, click here.

Question 5:

New CDC data show that the prevalence of obesity among 2- to 5-year-old children dropped from nearly 14% in 2003-2004 to slightly more than 8% in 2011-2012, a 43% decline.

ANSWER KEY »

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

ANSWER KEY:

Question 1. B

Question 2. A

Question 3. E

Question 4. D

Question 5. E

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 15th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

June 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

January 8th 2025

FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

December 23rd 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 15th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

June 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

January 8th 2025

FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

December 23rd 2024